Vyvgart, an FcRn inhibitor already approved for generalized myasthenia gravis, is also being tested in myositis, Sjögren’s ...
Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting ...
ACTION3 is a pivotal multicentre, randomised, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in ...
Long-term follow-up in the PALLAS study showed no overall survival benefit with palbociclib plus endocrine therapy compared to endocrine therapy alone in hormone receptor-positive, HER2-negative ...
Only 6% of trials for FDA-approved drugs match America's diversity. Analysis reveals how trial location and design choices ...
Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, ...
Over the past two decades, many emerging markets and developing economies have been viewed as increasingly resilient to ...
IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 December 9, 2025 12:30 PM ESTCompany ParticipantsShaun Bagai - ...
Counterfeit pharmaceuticals jeopardize public health worldwide, often leading to ineffective or dangerous treatments. Enter ...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase ...
Should I pickup Luther Burden III or Colston Loveland as fantasy football waiver wire pickups for Week 14 of 2025? Read our ...
Data showed encouraging results in patients with higher CLDN18.2 expression regardless of PD-L1 expression level, with a median PFS of 16.6 months, ORR of 68% and median DoR of 18 months ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback